Ivan Shirinsky
Overview
Explore the profile of Ivan Shirinsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nash P, Mease P, Fleishaker D, Wu J, Coates L, Behrens F, et al.
Lancet Rheumatol
. 2024 Jan;
3(1):e28-e39.
PMID: 38273637
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. This study evaluated the efficacy and safety of tofacitinib 5 mg...
2.
Shirinsky I, Kalinovskaya N, Filatova K, Shirinsky V
Int J Rheum Dis
. 2023 Jun;
26(11):2344-2346.
PMID: 37345895
No abstract available.
3.
Yakovlev A, Teplyakov A, Grakova E, Shilov S, Yakovleva N, Kopeva K, et al.
Life (Basel)
. 2023 Mar;
13(3).
PMID: 36983783
Heart failure with preserved ejection fraction (HFpEF) and obstructive sleep apnea (OSA) frequently co-occur and this comorbidity represents a separate phenotype of HFpEF. While many research attempts are focused on...
4.
Neogi T, Hunter D, Churchill M, Shirinsky I, White A, Guermazi A, et al.
Arthritis Res Ther
. 2022 Mar;
24(1):78.
PMID: 35351194
Background: A recent phase 3 study demonstrated that treatment with tanezumab, a nerve growth factor inhibitor, or nonsteroidal anti-inflammatory drugs (NSAIDs) improves pain and physical function in participants with moderate-to-severe...
5.
Putrik P, Ramiro S, Guillemin F, Pentek M, Sivera F, Sokka T, et al.
Ann Rheum Dis
. 2019 Aug;
78(11):1472-1479.
PMID: 31427438
Objectives: To describe and explore differences in formal regulations around sick leave and work disability (WD) for patients with rheumatoid arthritis (RA), as well as perceptions by rheumatologists and patients...
6.
Nogueira-Recalde U, Lorenzo-Gomez I, Blanco F, Loza M, Grassi D, Shirinsky V, et al.
EBioMedicine
. 2019 Jul;
45:588-605.
PMID: 31285188
Background: Ageing-related failure of homeostasis mechanisms contributes to articular cartilage degeneration and osteoarthritis (OA), for which disease-modifying treatments are not available. Our objective was to identify molecules to prevent OA...
7.
Shirinsky I, Shirinsky V
Arthritis Res Ther
. 2018 Jun;
20(1):116.
PMID: 29880063
Background: There is growing evidence that mast cells (MCs) play a role in knee osteoarthritis (OA). H-antihistamines block H-receptors of histamine, which is an important mediator of MCs. There is...
8.
Shirinsky I, Polovnikova O, Kalinovskaya N, Shirinsky V
Rheumatol Int
. 2012 Dec;
33(12):3045-8.
PMID: 23263548
Peroxisome proliferator-activated receptors α (PPARα) agonists, or fibrates, are used in the treatment for dyslipidemia. Experimental data suggest that fibrates have anti-inflammatory properties, and PPARα is essential for the differentiation...